OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer

ConditionOvarian Cancer

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age18+

SponsorBeihua Kong

About this trial

To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women over 18 years old;

Pathologically confirmed as stage I-IV primary epithelial ovarian malignant tumor;

ECOG < 2;

The expected survival period exceeds 6 months;

Disqualifiers

Have had other malignant tumors within the last five years;

Have received any treatment for ovarian cancer;

Benign ovarian mass;

Non-primary ovarian tumors;

Trial population

Patients with ovarian cancer

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

OCS product inspection

Time frame

Before the operation

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Beihua Kong

Lead sponsor

Shandong University

Sponsor institution

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: